- Home/
- Search results for GMP, GDP
SITE SEARCH
1〜10/35
-
Fundamentals of Microbiology [Part 8]
What Are Viruses? We often hear the term "computer virus", which is, of course, malicious software (a program). It is itself just a collection of 0s and 1s and is not a living organism, of course. When that software invades (infects) a PC, it causes various troubles. In other words, a computer virus can do nothing on its own, but once it invades an external entity called a computer, it starts to act like a living organism. The original virus behaves very similarly to a computer virus. (Or rather, it is correct to say that a computer virus is very similar to the original virus.) The main body of a virus is genetic information, that is, nucleic acid (DNA or RNA), and has a structure in which proteins surround the nucleic acid. Extremely speaking, a virus is a substance consisting of nucleic acid as its main body and surrounding proteins. Therefore, viruses do not have cells, and since they are chemical substances, viruses can be crystallized. Although viruses are chemical substances, once they invade the cells of another living organism, they can create (replicate) themselves using the biological functions of those cells. Viruses multiply themselves in other cells and destroy the cells when they break out. This is a viral disease. Generally, the size of viruses is about several tens to several hundreds of nanometers (nm; 10-9 meters), which is 2-3 orders of magnitude smaller than general bacteria. However, like the aforementioned giant bacteria, giant viruses such as Pandoravirus or Mimivirus, which are almost the same size as bacteria, have also been discovered in viruses. Speaking of viruses, the COVID-19 pandemic spread worldwide from 2020 to 2023. Therefore, the image of pathogens is inevitably strong, but not all viruses are pathogenic. The number of virus types is said to be...
https://cm-plus.co.jp/en/column/gmp/2026_1110/
-
[Vietnam] CM Plus Group to speak at GMP/EU-GMP WORKSHOP 2026 (Closed)
(Updated) Nov. 14, 2026 (Published) Sep. 14, 2026 On November 5–6, 2026, the ISPE Singapore – VNPCA GMP/EU-GMP Workshop was successfully held in Ho Chi Minh City, Vietnam, bringing together a large number of experts, regulatory leaders, and business representatives from the pharmaceutical and life sciences industries nationwide. The ISPE Singapore – VNPCA GMP Conference is an annual event co-organized by the ISPE Singapore Affiliate and the Vietnam Pharmaceutical Companies Association (VNPCA). It serves as a premier forum for industry professionals to exchange knowledge, share insights, and discuss best practices in Good Manufacturing Practice (GMP). This year’s conference took place on November 5–6, 2026, in Ho Chi Minh City, Vietnam. CM Plus was honored to support the event as a sponsor and contribute technical insights through presentations by Mr. Tahara Shigehiro and Ms. Bui Thi Hong Loan, sharing our expertise and perspectives within the pharmaceutical engineering sector. [caption id="attachment_6745" align="aligncenter" width="600"] Presentation by Mr Tahara Shigehiro[/caption] During the workshop, our speakers shared practical experience and perspectives on risk-based Commissioning & Qualification (C&Q) approaches and contamination control strategies (CCS) for pharmaceutical and medical device manufacturing facilities. They also introduced E-Document and Pharmo AI solutions designed to enhance documentation and system management efficiency while ensuring compliance with current GMP requirements, including EU-GMP and PIC/S GMP. [caption id="attachment_6742" align="aligncenter" width="500"] Presentation by Ms. Bui Thi Hong Loan[/caption] The strong engagement and active participation of delegates during the Q&A and discussion sessions underscored the growing demand in Vietnam’s pharmaceutical sector for continuous knowledge updates, stronger regulatory compliance capabilities, and the adoption of advanced engineering solutions. CM Plus extends its sincere appreciation to the ISPE Singapore Affiliate, VNPCA, as well as all speakers and delegates for making the conference a great success. We look forward to continuing our partnership with Vietnam’s pharmaceutical community, sharing our...
https://cm-plus.co.jp/en/news/event/2026_0914/
-
Japan’s PMDA Publishes Its First GMP Inspection Non-Compliance Notice
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has officially begun publishing GMP Inspection Non-Compliance Notices, marking a significant shift in its regulatory approach. This new policy is designed to enhance transparency within the pharmaceutical industry and serve as a preventative tool. By publicly detailing severe Good Manufacturing Practice (GMP) violations and the reasons for failing inspections, the PMDA aims to share critical "lessons learned" with the broader industry, encouraging proactive compliance and preventing the recurrence of systemic quality failures across other manufacturers. ■ Differences Between PMDA Non-Compliance Notices and U.S. FDA Warning Letters FDA Warning Letters and PMDA GMP inspection publications serve distinct regulatory functions. An FDA Warning Letter is a direct notification sent to a company to identify significant violations, such as poor manufacturing practices, requiring a time-bound response to outline corrective actions or provide reasoning for disagreement. Conversely, the PMDA's initiative is a program to publish GMP inspection statuses (pass/fail) on its website to improve transparency of PMDA’s supervision. The most critical difference is that the PMDA will only publish a "non-compliant" result if the inspected manufacturer provides explicit prior consent, unless the failure has already been reported by the media. ■ Details of the Inaugural Non-Compliance Notice The first publicly released GMP Inspection Non-Compliance Notice was issued by the Wakayama Prefectural Governor to Kasano Kosan Co., Ltd. on September 1, 2026, following on-site inspections conducted in February 2026. The document reveals critical and systemic failures rooted in deliberate falsification and the total collapse of the facility's pharmaceutical quality system. The notice outlines three primary categories of severe violations: 1. Fabrication of Stability Monitoring Data: The facility systematically mishandled Out-of-Specification (OOS) results during stability monitoring for multiple products. Under the direction of the Manufacturing Supervisor, the company failed to conduct mandatory testing, fabricated passing numerical values, and neglected...
https://cm-plus.co.jp/en/column/gmp/2026_1104/
-
Fundamentals of Microbiology [Part 7]
What Are Bacteria 2-2 Bacteria proliferate by division when the surrounding environment such as temperature, nutrients, oxygen, or osmotic pressure is suitable for the bacteria. This is where one bacterium becomes two, two become four, four become eight, eight become sixteen, and so on, doubling in number. The growth rate varies depending on the type of bacteria and surrounding environmental conditions, but for fast-growing bacteria such as Escherichia coli under optimal conditions, the time required for one division is said to be about 20 minutes. The time required for one division is called generation time. In this way, Escherichia coli can divide once every 20 minutes under optimal conditions, that is, three times per hour. If division continues at this rate, it will be as shown below. So if growth continues at this rate, how many viable bacteria will there be after one day? One day = 24 hours = 3 × 24 = 72 (generations). So putting 72 into n, the calculation is 2⁷² = 4.7 × 10²¹, an astronomical number. When this bacterial growth is plotted on a graph, it is as shown in Figure 1. The left side uses a normal scale, while the right side uses a logarithmic scale for the vertical axis. Figure 1 Microbial Growth Since microorganisms (bacteria) proliferate by binary fission, if the surrounding environment and nutritional status are suitable for the microorganisms, they can reach an enormous number in a short time. However, in reality, when the number of viable bacteria in the medium reaches about 109 to 1010 /ml (1 billion to 10 billion per 1 ml), the growth rate slows down due to depletion of available nutrients, pH changes due to accumulation of metabolic products, etc., and eventually stops, leading to death. The extent of proliferation varies depending on the...
https://cm-plus.co.jp/en/column/gmp/2026_1102/
-
GMP WATCH NEWS – A Veteran’s Perspective[3]
Paradigm Shifts in Pharmaceutical Quality Systems A Historical Review and Future Perspectives [Part 3] From QC to the Pharmaceutical Quality System (PQS) When GMP was first introduced in 1963, the “testing” conducted by the QC department played a central role. However, as GMP evolved, there was a dramatic increase in complex tasks beyond testing, such as document control, change control, and deviation management. Consequently, the FDA revised CGMP in 1978, significantly strengthening the authority of the QC department. It clarified the department’s independence from the manufacturing department and its final authority over release decisions, effectively mandating that the QC department also assume the current role of Quality Assurance (QA). Furthermore, in 1987, the ISO 9000 Series (Quality Management Systems) was established, clearly defining the term “Quality Assurance (QA)” and spreading it worldwide. This marked the point at which QC, responsible for testing, and QA, responsible for ensuring the integrity of the entire system, became clearly distinguished. In 2008, ICH Q10 introduced the concept of a “Pharmaceutical Quality System (PQS),” which includes management responsibility. QA was redefined not merely as an on-site monitor, but as a department responsible for quality assurance at the management level. By the way, the term “Quality Unit (QU)” was first used in ICH Q7, “Guideline on Good Manufacturing Practice for Pharmaceutical Active Substances,” published in 2000, where a QU was defined as an organization responsible for both QC and QA. Furthermore, in the FDA guidance document “Quality System Approach” published in 2006, the traditional regulatory term “Quality Control Unit” was replaced with “Quality Unit.” Due to the historical evolution of GMP, department names vary widely: some companies have QA functions within their “QC units,” while others have “QA units” that also perform testing; in smaller factories, a single department may handle everything. Therefore, we have decided...
https://cm-plus.co.jp/en/column/gmp/2026_1023/
-
Fundamentals of Microbiology [Part 6]
What Are Bacteria 2-1 Bacteria are representative of microorganisms, and the term is widely known, but only few people may explain them clearly. Living organisms are made of cells. Note) Cells are roughly divided into two types. Simply put, they can be called "lower organisms" and "higher organisms", but they are prokaryotic cells without a cell nucleus and eukaryotic cells with intracellular structures such as a cell nucleus or mitochondria. Bacteria are representative of these lower prokaryotic cells. Incidentally, eukaryotic cells are cells of animals, plants, fungi, etc., and are considered higher organisms than prokaryotic cells. Note) All living organisms from microorganisms such as bacteria to humans have cells as their basic unit. However, viruses do not have a cellular structure. This is also a point of debate as to whether viruses are living organisms or not. Bacterial cells are surrounded by a tough cell wall like an eggshell, and there is a cell membrane inside. Bacteria are "single-celled organisms" where each individual consists of one cell and reproduces by binary fission. The size of one cell is about 0.2 to several micrometers (1 μm = 1/1000 mm), and individual cells cannot be seen with the naked eye. Note) Note) Recently, there have been reports that "giant white filamentous bacteria up to 2 cm in size have been discovered", but this is an exception. Generally, the size of bacteria is at most several micrometers, so they cannot be seen with the naked eye. Currently, bacteria are classified based on the base sequence of the 16S rRNA gene. However, historically, they were classified by their morphology and simple biochemical properties. Therefore, the shape and properties of bacteria are still important guidelines for understanding bacteria even today. Bacteria are morphologically divided into cocci, bacilli, and spirilla. Cocci include Staphylococcus or Streptococcus, which...
https://cm-plus.co.jp/en/column/gmp/2026_1019/
-
GMP WATCH NEWS – A Veteran’s Perspective[2]
Paradigm Shifts in Pharmaceutical Quality Systems A Historical Review and Future Perspectives [Part 2] Implementation of Process Validation The concept of validation has its roots in the space technology developed during the U.S. Apollo program (1960s). Launch rockets are single-use. The concept of sampling inspection—where one might say, “Let’s test-launch it; since it worked, we’ll launch it again”—simply does not apply. Therefore, NASA rigorously applied the principles of reliability engineering—the idea that “if the design and manufacturing processes are flawless, the final product must also be flawless”—and established the prototype for the concept of validation. FDA officials wondered, “Why isn’t the same level of precision in quality assurance found in the rocket industry being applied to the pharmaceutical industry, where human lives are at stake?” and introduced the NASA-derived approach of “building quality into the process” into the world of GMP. It can be said that validation is a technology “adapted from the pharmaceutical world to the quality assurance techniques cultivated in NASA’s Apollo program—an environment where failure was not an option.” Understanding this background should help explain why validation places such a strong emphasis on “documentation” and “advance planning.” The definition of process validation issued in 1987 was “the establishment of evidence that provides a high degree of assurance that a process can consistently produce products that meet specified standards and quality characteristics.” But what does “consistently produce” actually mean? Since the definition provided only a conceptual framework without specifying concrete methods for validating pharmaceutical manufacturing processes, it caused considerable confusion among regulatory authorities and pharmaceutical companies worldwide. The FDA must have been quite troubled by this as well; in 1993, the FDA specifically presented “the successful production of three consecutive batches at actual production scale” as a requirement for completing validation. This became widely recognized within the industry,...
https://cm-plus.co.jp/en/column/gmp/2026_0928/
-
GMP WATCH NEWS – A Veteran’s Perspective
Paradigm Shifts in Pharmaceutical Quality Systems A Historical Review and Future Perspectives [Part 1] Introduction It has been nearly half a century since I first became involved in pharmaceutical GMP. During that time, GMP has evolved significantly, and unfamiliar GMP-related technical terms—such as “validation” and “qualification”—have been introduced. As GMP has evolved, I feel that the meanings and usage of these terms have shifted subtly. I wrote this article to clarify the meanings of these confusing terms by sharing stories from my own experience with GMP. I hope this helps readers understand that “GMP is not a law, but a science for ensuring quality.” The Birth of GMP I’m sure many of you have felt frightened after seeing news reports of mobile batteries suddenly catching fire inside carry-on luggage on planes or trains. While factors such as the product being subjected to a strong impact could be causes of the fire, I understand that in many cases, the user is not at fault. According to news reports, there is no doubt that changes in manufacturing processes resulting from intense price competition are a contributing factor to these accidents. I am shocked—and even angered—by the fact that companies, which should be responsible for product quality, do not know where the parts were made or how the products were assembled, and by their lack of a proper response. However, even in the Japanese pharmaceutical industry several decades ago, efforts to improve processes with the aim of reducing costs and enhancing quality were encouraged. While process yield and productivity did indeed improve, these changes were not managed in accordance with established rules. As a result, situations arose where it was unclear when, by whom, or how changes had been made. Although manufacturing instructions did exist, they were not updated every time a change...
https://cm-plus.co.jp/en/column/gmp/2026_0825/
-
PMDA ORANGE LETTER_2026.07
ORANGE LETTER To encourage voluntary quality improvements at pharmaceutical manufacturing sites, Japanese regulatory agency PMDA has been publishing anonymized, highly useful findings from its inspections based on Japanese GMP Ministerial Order. These are published in a format known as the "ORANGE Letter" since 2022. CM Plus provides abridged English translations of the Orange Letters, for our clients' reference. Observed Regulatory Attention/Notification of GMP Elements LETTER Author: PMDA Issue: July 2026 Title: Airflow Visualization Testing (Smoke Testing) in Aseptic Areas Related GMP Ministerial Ordinance Clause: Article 24-3 Cases Defects in product contamination prevention control were observed. In a smoke test conducted in an aseptic area, the site failed to detect the product contamination risk suggested by the test results, and there were omissions in some of the evaluations. Background ♦Regarding the production control of sterile pharmaceuticals, the GMP Ministerial Order stipulates that necessary measures be taken to prevent contamination of starting materials, packaging/labeling materials, and products from contamination, etc. by microorganisms, etc.. ♦PIC/S GMP Guidelines Annex 1 specifies that airflow pattern under all actual operational conditions should be evaluated to confirm that contamination risks from personnel, equipment, etc., are adequately controlled. Observations ♦Upon reviewing the video of a smoke test conducted in the aseptic area of a freeze-dried product line, it was observed that air coming into contact with the operator who is transferring the product to the freeze dryer was flowing into the openings of partially stoppered vials. However, the potential risk of this airflow on product sterility had not been evaluated. Furthermore, smoke tests for certain processes had not been conducted. ♦When reviewing the results of environmental monitoring for the aseptic area of the production line, microorganisms suspected to be derived from operators were found. This suggested the possibility that contamination prevention measures in the aseptic area were not...
https://cm-plus.co.jp/en/column/gmp/2026_0814/
-
PMDA ORANGE LETTER_2026.06
ORANGE LETTER To encourage voluntary quality improvements at pharmaceutical manufacturing sites, Japanese regulatory agency PMDA has been publishing anonymized, highly useful findings from its inspections based on Japanese GMP Ministerial Order. These are published in a format known as the "ORANGE Letter" since 2022. CM Plus provides abridged English translations of the Orange Letters, for our clients' reference. Observed Regulatory Attention/Notification of GMP Elements LETTER Author: PMDA Issue: June 2026 Title: Management of Expiration Date and Retest Period of API - Preventing Misunderstandings Regarding Retest Related GMP Ministerial Ordinance Clause: Article 3-2, etc. Cases Due to insufficient understanding of the definitions of the expiration date and the retest period APIs, established procedures allowed for the use of APIs even after their expiration date by repeatedly conducting retests on the APIs intended for manufacturing. Background ♦Regarding the storage of APIs, the GMP Ministerial Order requires management under appropriate conditions that do not give impact to quality. ♦For APIs with an "expiration date" specified in the approval document, they can only be used during this valid period and never can be used after their expiration date. On the other hand, for APIs with a specified "retest period", they can be used during the retest period, and even after the retest period has passed, they can be used if they pass a retest immediately prior to use (Refer to GMP Case Studies 1) GMP 21-4). Observations ♦At the manufacturing site, tablets were manufactured using an API with an expiration date specified in the approval document. However, the procedure is specified in a way that allows for the use of API after the expiration date by conducting a retest. ♦Specifically, with the intention of reducing raw material waste and ensuring a stable product supply, the related SOP stipulated: "In principle, APIs that have exceeded...
https://cm-plus.co.jp/en/column/gmp/2026_0803/


